Preliminary experience with controlled-release aminophylline in asthmatic children: salivary levels and peak flow following a single dose.
Preliminary experience of a controlled-release aminophylline tablet in twenty-five asthmatic children has been gained by measuring salivary theophylline levels and peak flow after a single dose (11 mg/kg). The results were compared with an oral theophylline preparation. Mean salivary levels remained elevated at eight hours following ingestion of controlled-release aminophylline, at which time 58% of the children continued to show an improvement in peak flow. Individual children showed a wide variation in salivary levels and respiratory response. It is recommended that theophylline levels should be monitored in the saliva to ensure maximum benefit from the drug.
D000293:Adolescent; D000628:Aminophylline / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D002648:Child; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D005260:Female; D005540:Forced Expiratory Flow Rates; D006801:Humans; D008297:Male; D010366:Peak Expiratory Flow Rate; D012463:Saliva / Q000378:metabolism*; D013997:Time Factors
D003692:Delayed-Action Preparations; D000628:Aminophylline